GSK Enters Race For OTC COVID-19 Test With Mammoth Biosciences As Partner
GSK partners with biotech firm Mammoth Biosciences to develop a home-use OTC nasal swab test for COVID-19 that works in less than 20 minutes. Mammoth says the firms will seek an FDA emergency use authorization for the test, roll it out first to clinics and will seek approval for OTC sales.
You may also be interested in...
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.
Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.
The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.